$BIOCQ
Biocept Inc Stock $biocq

$biocq Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000156459019009914 Filed on March 29, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$1.024M	$859.5K	$761.6K
YoY Change	26.93%	-13.64%	-31.48%
Cost Of Revenue	$2.599M	$2.435M	$2.482M
YoY Change	6.76%	3.19%	-0.21%
Gross Profit	-$1.575M	-$1.576M	-$1.720M
YoY Change	-3.24%	15.47%	25.06%
Gross Profit Margin	-153.78%	-183.33%	-225.89%
Selling, General & Admin	$3.056M	$3.073M	$3.198M
YoY Change	-14.51%	-6.67%	-8.91%
% of Gross Profit
Research & Development	$1.223M	$1.289M	$1.090M
YoY Change	14.26%	41.83%	27.2%
% of Gross Profit
Depreciation & Amortization	$220.0K	$220.0K	$223.2K
YoY Change	22.22%	15.79%	39.89%
% of Gross Profit
Operating Expenses	$4.280M	$4.362M	$4.288M
YoY Change	-7.88%	3.82%	-1.82%
Operating Profit	-$5.855M	-$5.938M	-$6.008M
YoY Change	-6.68%	6.68%	4.61%
Interest Expense	-$60.00K	-$80.00K	$63.76K
YoY Change	-172.57%	-20.0%	-170.85%
% of Operating Profit
Other Income/Expense, Net		$10.00K	-$39.80K
YoY Change			-47.26%
Pretax Income	-$5.920M	-$6.010M	-$6.048M
YoY Change	-6.87%	6.18%	3.94%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.917M	-$6.014M	-$6.048M
YoY Change	-6.92%	6.14%	3.89%
Net Earnings / Revenue	-577.68%	-699.72%	-794.1%
Basic Earnings Per Share	-$0.61	-$1.43	-$2.42
Diluted Earnings Per Share	-$0.61	-$1.43	-$2.42
COMMON SHARES
Basic Shares Outstanding	18.82M	4.209M	2.767M
Diluted Shares Outstanding	9.792M	4.209M	2.760M

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.76M	$3.420M	$8.960M
YoY Change	59.22%	59.07%	52.38%
Cash & Equivalents	$14.76M	$3.423M	$8.956M
Short-Term Investments
Other Short-Term Assets	$270.0K	$430.0K	$640.0K
YoY Change	-59.7%	2.38%	56.1%
Inventory	$580.0K	$587.2K	$580.0K
Prepaid Expenses
Receivables	$1.880M	$1.574M	$1.480M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.49M	$6.011M	$11.65M
YoY Change	48.72%	41.26%	42.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.400M	$2.739M	$2.900M
YoY Change	47.16%	-12.3%	-0.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.402M	$2.739M	$2.902M
YoY Change	47.33%	-12.3%	-0.63%
TOTAL ASSETS
Total Short-Term Assets	$17.49M	$6.011M	$11.65M
Total Long-Term Assets	$4.402M	$2.739M	$2.902M
Total Assets	$21.89M	$8.750M	$14.55M
YoY Change	48.44%	18.59%	30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.260M	$2.040M	$1.790M
YoY Change	62.59%	60.61%	12.58%
Accrued Expenses	$3.520M	$1.928M	$1.950M
YoY Change	55.07%	10.05%	-10.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$120.0K
YoY Change	-100.0%	-100.0%	0.0%
Long-Term Debt Due	$640.0K	$640.0K	$570.0K
YoY Change	-44.35%	-59.49%	-70.77%
Total Short-Term Liabilities	$6.430M	$4.610M	$4.440M
YoY Change	31.76%	-1.08%	-23.97%
LONG-TERM LIABILITIES
Long-Term Debt	$970.0K	$990.0K	$1.020M
YoY Change	-13.39%	-13.91%	7.37%
Other Long-Term Liabilities	$480.0K	$110.0K	$160.0K
YoY Change	108.7%	-59.26%	-48.39%
Total Long-Term Liabilities	$1.452M	$1.098M	$1.174M
YoY Change	7.0%	-22.75%	-6.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.430M	$4.610M	$4.440M
Total Long-Term Liabilities	$1.452M	$1.098M	$1.174M
Total Liabilities	$7.880M	$5.708M	$5.610M
YoY Change	26.28%	-6.17%	-20.87%
SHAREHOLDERS EQUITY
Retained Earnings		-$220.5M
YoY Change		12.91%
Common Stock		$223.5M
YoY Change		13.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.01M	$3.043M	$8.938M
YoY Change
Total Liabilities & Shareholders Equity	$21.89M	$8.750M	$14.55M
YoY Change	48.41%	18.59%	30.85%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$5.917M	-$6.014M	-$6.048M
YoY Change	-6.92%	6.14%	3.89%
Depreciation, Depletion And Amortization	$220.0K	$220.0K	$223.2K
YoY Change	22.22%	15.79%	39.89%
Cash From Operating Activities	-$5.248M	-$5.420M	-$5.460M
YoY Change	-5.89%	-5.74%	10.3%
INVESTING ACTIVITIES
Capital Expenditures	$32.90K	$0.00	-$80.00K
YoY Change	-39.06%	-100.0%	-84.91%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$32.90K	$0.00	-$80.00K
YoY Change	-39.06%	-100.0%	-84.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.500M
YoY Change			13.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.62M	-110.0K	11.91M
YoY Change	30.29%	-104.64%	782.22%
NET CHANGE
Cash From Operating Activities	-5.248M	-5.420M	-5.460M
Cash From Investing Activities	-32.90K	0.000	-80.00K
Cash From Financing Activities	16.62M	-110.0K	11.91M
Net Change In Cash	11.34M	-5.530M	6.370M
YoY Change	59.12%	48.66%	-254.24%
FREE CASH FLOW
Cash From Operating Activities	-$5.248M	-$5.420M	-$5.460M
Capital Expenditures	$32.90K	$0.00	-$80.00K
Free Cash Flow	-$5.280M	-$5.420M	-$5.380M
YoY Change	-6.21%	0.18%	21.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18817076
CY2018Q2	dei	Entity Public Float EntityPublicFloat	13554726
CY2017Q4	us-gaap	Cash Cash	2146611
CY2018Q4	us-gaap	Cash Cash	3423373
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1193426
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1574325
CY2017Q4	us-gaap	Inventory Net InventoryNet	498702
CY2018Q4	us-gaap	Inventory Net InventoryNet	587222
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416600
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	425961
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4255339
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6010881
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3123567
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2739422
CY2017Q4	us-gaap	Assets Assets	7378906
CY2018Q4	us-gaap	Assets Assets	8750303
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1269953
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2039718
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1752363
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1928393
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23777233
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	719000
CY2017Q4	bioc	Supplier Financings SupplierFinancings	61226
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	408992
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	641536
CY2017Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1168811
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	51216
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7624
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-21613737
CY2018	bioc	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	636370
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21613737
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25207971
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1247481
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7498535
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	575717
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800905
CY2017	bioc	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	50532
CY2018	bioc	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	38499
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1247481
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	623412
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	45788
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	29426
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1064457
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	380899
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-100875
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50021
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-518863
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-488505
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	349932
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	601872
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	236927
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	460972
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	78649
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-202609
CY2017	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-76232
CY2018	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-116681
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19650726
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22355218
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1400180
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	145253
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1400180
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-145253
CY2017	bioc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13505094
CY2018	bioc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	25693474
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7498535
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1200
CY2017	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	150848
CY2017	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	166348
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	160381
CY2017	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	465279
CY2018	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	559092
CY2017	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1934665
CY2017Q4	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2018-06-05
CY2017Q4	bioc	Class Of Warrant Or Right Expiry Period ClassOfWarrantOrRightExpiryPeriod	P5Y
CY2017Q4	bioc	Class Of Warrants Or Rights Expiration Date ClassOfWarrantsOrRightsExpirationDate	2022-12-05
CY2017Q4	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	100000
CY2017Q4	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	428000
CY2018Q1	bioc	Shares Available For Public Offering SharesAvailableForPublicOffering	1095153
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1197968
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18588185
CY2017	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-2462721
CY2018	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	1276762
CY2016Q4	us-gaap	Cash Cash	4609332
CY2017	us-gaap	Interest Paid Net InterestPaidNet	358471
CY2018	us-gaap	Interest Paid Net InterestPaidNet	605485
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5273
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4517
CY2017	bioc	Financial Guarantee Insurance Contracts Premium Payable FinancialGuaranteeInsuranceContractsPremiumPayable	451000
CY2018	bioc	Financial Guarantee Insurance Contracts Premium Payable FinancialGuaranteeInsuranceContractsPremiumPayable	488000
CY2018	bioc	Financial Guarantee Insurance Contracts Cancelled Premium Remaining Principal Outstanding FinancialGuaranteeInsuranceContractsCancelledPremiumRemainingPrincipalOutstanding	0
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	279000
CY2017	bioc	Aggregate Net Book Value Of Fixed Assets AggregateNetBookValueOfFixedAssets	34000
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	25000
CY2017Q1	bioc	Issuance Of Unregistered Warrants To Purchase Common Stock Shares IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares	72000
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	75.00
CY2017Q1	bioc	Class Of Warrant Or Right Expiry Period ClassOfWarrantOrRightExpiryPeriod	P5Y
CY2017Q1	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	2800000
CY2017Q1	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	728000
CY2017Q3	bioc	Issuance Of Unregistered Warrants To Purchase Common Stock Shares IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares	47821
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	45.00
CY2017Q3	bioc	Class Of Warrant Or Right Expiry Period ClassOfWarrantOrRightExpiryPeriod	P5Y
CY2017Q3	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	1500000
CY2017Q3	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	176000
CY2017Q4	bioc	Issuance Of Unregistered Warrants To Purchase Common Stock Shares IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares	8208
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	25.50
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.16
CY2018Q1	bioc	Class Of Warrant Or Rights Term ClassOfWarrantOrRightsTerm	P5Y
CY2018Q1	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	9700000
CY2018Q1	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	1400000
CY2018Q3	bioc	Aggregate Number Of Units Sold Pursuant To Right Offering AggregateNumberOfUnitsSoldPursuantToRightOffering	11587
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.53
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11600000
CY2018Q3	bioc	Class Of Warrant Or Rights Term ClassOfWarrantOrRightsTerm	P5Y
CY2018Q3	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	8400000
CY2018Q3	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	1400000
CY2018Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1584571
CY2018Q3	bioc	Shares Available For Public Offering SharesAvailableForPublicOffering	642438
CY2018Q3	us-gaap	Share Price SharePrice	3.285
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2500000
CY2018Q3	bioc	Unregistered Warrants Issued Grant Date Fair Value UnregisteredWarrantsIssuedGrantDateFairValue	2000000
CY2018Q3	bioc	Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital	300000
CY2018Q3	bioc	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	636000
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was founded in California in May 1997 and is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, Empower TC, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, <font style="color:#000000;">sales to laboratory supply distributors of </font>our proprietary blood collection tubes, or BCTs, <font style="color:#000000;">commenced in June 2018, </font>which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p>
CY2017	bioc	Provisions For Aged Non Patient Receivables ProvisionsForAgedNonPatientReceivables	735709
CY2017	bioc	Provisions For Estimated Patient Receivables ProvisionsForEstimatedPatientReceivables	169479
CY2017	bioc	Provisions For Other Payer Specific Sales Allowances ProvisionsForOtherPayerSpecificSalesAllowances	5403757
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accounts receivable, inventories, long-lived assets, income taxes, revenues, stock-based compensation, and the determination of the Company’s ability to continue as a going concern. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the years ended December 31, 2017 and 2018 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2017 and 2018 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company’s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p>
CY2017	bioc	Nonrecurring Net Revenue Recognized On Accrual Basis Associated With Cases Delivered NonrecurringNetRevenueRecognizedOnAccrualBasisAssociatedWithCasesDelivered	843000
CY2017Q4	bioc	Aggregate Net Interest Bearing Indebtedness AggregateNetInterestBearingIndebtedness	3100000
CY2018Q4	bioc	Aggregate Net Interest Bearing Indebtedness AggregateNetInterestBearingIndebtedness	1600000
CY2017Q4	bioc	Aggregate Net Interest Bearing Indebtedness Due Within One Year AggregateNetInterestBearingIndebtednessDueWithinOneYear	2000000
CY2018Q4	bioc	Aggregate Net Interest Bearing Indebtedness Due Within One Year AggregateNetInterestBearingIndebtednessDueWithinOneYear	642000
CY2017Q4	bioc	Other Non Interest Bearing Current Liabilities OtherNonInterestBearingCurrentLiabilities	2700000
CY2016Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	1062500
CY2018	bioc	Unconditional Purchase Commitment Frequency Of Periodic Payment UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment	Quarterly
CY2018	us-gaap	Unrecorded Unconditional Purchase Obligation Date UnrecordedUnconditionalPurchaseObligationDate	2020-05-31
CY2018Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	341000
CY2017Q3	bioc	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	2000000
CY2017Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2200000
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	45.00
CY2017Q3	bioc	Warrants Exercisable Exercise Price Per Share Expiration Period WarrantsExercisableExercisePricePerShareExpirationPeriod	2022-08
CY2018Q2	bioc	Public Float Minimum Limit For Offering PublicFloatMinimumLimitForOffering	75000000
CY2018Q3	bioc	Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering	10100000
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	642438
CY2018Q3	bioc	Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering	2200000
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.03
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2018Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock.
CY2017	bioc	Net Revenues From Contracted Payers NetRevenuesFromContractedPayers	2074596
CY2018	bioc	Net Revenues From Contracted Payers NetRevenuesFromContractedPayers	1348383
CY2017	bioc	Net Revenues From Non Contracted Payers NetRevenuesFromNonContractedPayers	2721717
CY2018	bioc	Net Revenues From Non Contracted Payers NetRevenuesFromNonContractedPayers	1703179
CY2017	bioc	Development Services Net Revenue DevelopmentServicesNetRevenue	272350
CY2018	bioc	Development Services Net Revenue DevelopmentServicesNetRevenue	198736
CY2017	bioc	Net Commercial Revenues Recognized Upon Delivery NetCommercialRevenuesRecognizedUponDelivery	3570337
CY2018	bioc	Net Commercial Revenues Recognized Upon Delivery NetCommercialRevenuesRecognizedUponDelivery	3051562
CY2017	bioc	Net Development Services Revenues Recognized Upon Delivery NetDevelopmentServicesRevenuesRecognizedUponDelivery	272350
CY2018	bioc	Net Development Services Revenues Recognized Upon Delivery NetDevelopmentServicesRevenuesRecognizedUponDelivery	198736
CY2017	bioc	Net Commercial Revenues Recognized Upon Cash Collection NetCommercialRevenuesRecognizedUponCashCollection	1225976
CY2018Q4	bioc	Common Stock Warrants Outstanding Intrinsic Value CommonStockWarrantsOutstandingIntrinsicValue	0
CY2017	bioc	Increase Decrease In Net Income Loss Per Common Share On Nonrecurring Net Revenue IncreaseDecreaseInNetIncomeLossPerCommonShareOnNonrecurringNetRevenue	-0.90
CY2017	bioc	Net Revenue Recorded In Excess Of Commercial Cash Collections NetRevenueRecordedInExcessOfCommercialCashCollections	1139000
CY2017	bioc	Increase Decrease In Net Income Loss Per Common Share IncreaseDecreaseInNetIncomeLossPerCommonShare	-1.20
CY2017	bioc	Commercial Revenues Recognized Upon Delivery Gross CommercialRevenuesRecognizedUponDeliveryGross	15685069
CY2018	bioc	Commercial Revenues Recognized Upon Delivery Gross CommercialRevenuesRecognizedUponDeliveryGross	12505149
CY2017	bioc	Development Services Revenues Recognized Upon Delivery Gross DevelopmentServicesRevenuesRecognizedUponDeliveryGross	272350
CY2018	bioc	Development Services Revenues Recognized Upon Delivery Gross DevelopmentServicesRevenuesRecognizedUponDeliveryGross	198736
CY2017	bioc	Commercial Revenues Recognized Upon Cash Collection Gross CommercialRevenuesRecognizedUponCashCollectionGross	1225976
CY2017	bioc	Sales Revenue Goods Gross1 SalesRevenueGoodsGross1	17183395
CY2018	bioc	Sales Revenue Goods Gross1 SalesRevenueGoodsGross1	12703885
CY2017	bioc	Provisions For Contractual Discounts ProvisionsForContractualDiscounts	5805787
CY2018	bioc	Provisions For Contractual Discounts ProvisionsForContractualDiscounts	3937993
CY2018	bioc	Provisions For Aged Non Patient Receivables ProvisionsForAgedNonPatientReceivables	326137
CY2018	bioc	Provisions For Estimated Patient Receivables ProvisionsForEstimatedPatientReceivables	66470
CY2018	bioc	Provisions For Other Payer Specific Sales Allowances ProvisionsForOtherPayerSpecificSalesAllowances	5122987
CY2017Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	1193426
CY2018	bioc	Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery	3250298
CY2018	bioc	Gross And Net Accounts Receivable For Settlements Upon Adjudication GrossAndNetAccountsReceivableForSettlementsUponAdjudication	-2869399
CY2018Q4	bioc	Gross And Net Accounts Receivable GrossAndNetAccountsReceivable	1574325
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018	us-gaap	Concentration Risk Supplier ConcentrationRiskSupplier	one supplier
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2015Q2	bioc	Shelf Registration Statement Expiration Period ShelfRegistrationStatementExpirationPeriod	2018-05-21
CY2018Q3	bioc	Conversion Of Preferred Stock To Common Stock Conversion Price ConversionOfPreferredStockToCommonStockConversionPrice	4.53
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	39.30
CY2017Q3	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	30.90
CY2017Q4	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	15.60
CY2018Q1	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	8.82
CY2018Q3	bioc	Issuance Of Unregistered Warrants To Purchase Common Stock Shares IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares	2549140
CY2018Q3	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	3.30
CY2018Q3	bioc	Issuance Of Unregistered Warrants To Purchase Common Stock Shares IssuanceOfUnregisteredWarrantsToPurchaseCommonStockShares	762438
CY2018Q3	bioc	Estimated Grant Date Fair Value Of Warrants EstimatedGrantDateFairValueOfWarrants	2.57
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2841388
CY2018Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2818583
CY2017Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147976
CY2018Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	157391
CY2017Q4	bioc	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	1637034
CY2018Q4	bioc	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	1437408
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	553529
CY2018Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	570173
CY2017Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	2294762
CY2018Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	2573955
CY2017Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2975
CY2018Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	116640
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7477664
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7674150
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4354097
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4934728
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	326602
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	224813
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	255426
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	474953
CY2018Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	535682
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	375000
CY2018Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	712574
CY2017Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	104509
CY2018Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	62767
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	116681
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	158342
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129805
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203602
CY2017Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	759000
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	1135000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	670896
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	551610
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	305006
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	264600
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	310932
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	2103044
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	476493
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	1626551
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due Current CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueCurrent	91285
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due In Two Years CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears	72635
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due In Three Years CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears	51473
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due In Four Years CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFourYears	60832
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due Thereafter CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter	45710
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Due CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsDue	321935
CY2018Q4	bioc	Capital Leases Maintenance And Sales Tax Obligation Payments Net CapitalLeasesMaintenanceAndSalesTaxObligationPaymentsNet	321935
CY2017	bioc	Equipment Financings Aggregate Weighted Average Interest Rate EquipmentFinancingsAggregateWeightedAverageInterestRate	0.1351
CY2018	bioc	Equipment Financings Aggregate Weighted Average Interest Rate EquipmentFinancingsAggregateWeightedAverageInterestRate	0.1253
CY2018	bioc	Equipment Financings Maturity Date Range Start EquipmentFinancingsMaturityDateRangeStart	2018-06
CY2018	bioc	Equipment Financings Maturity Date Range End EquipmentFinancingsMaturityDateRangeEnd	2024-09
CY2018Q4	bioc	Equipment Financings Minimum Payments Present Value Due Within One Year EquipmentFinancingsMinimumPaymentsPresentValueDueWithinOneYear	642000
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	250000
CY2018Q1	bioc	Number Of Lease Payments NumberOfLeasePayments	22
CY2018Q1	bioc	Lease Payments Per Month LeasePaymentsPerMonth	15274
CY2018Q4	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	332000
CY2018	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	332000
CY2018	bioc	Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans	2
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29888
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	58501
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6746
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	81643
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	142587
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	28410
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	195820
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	183136
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	264.00
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	44.70
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	143.10
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	113.68
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	57.96
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.41
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	44.02
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M6D
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M17D
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.16
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	381886
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5867281
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	215000
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	90000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	bioc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Decrease In Net Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDecreaseInNetDeferredTaxAssets	2600000
CY2018	bioc	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit	2600000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7624
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1886
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7624
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1886
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7346079
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5159881
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	2621803
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-411853
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-670015
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	214313
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	118959
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	72696
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	11128
CY2017	bioc	Income Tax Reconciliation Nondeductible Expense Interest IncomeTaxReconciliationNondeductibleExpenseInterest	15568
CY2017	bioc	Income Tax Reconciliation Expiration Of Net Operating Losses IncomeTaxReconciliationExpirationOfNetOperatingLosses	922307
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	200379
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	272314
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	-18026
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	-132855
CY2017	bioc	Income Tax Reconciliation Section Three Eight Two Limitation IncomeTaxReconciliationSectionThreeEightTwoLimitation	1491942
CY2017	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	365263
CY2018	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	8386
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	488264
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	19420
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1791805
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6079058
CY2017	bioc	Percent Of Uncertain Income Tax Positions Recognized PercentOfUncertainIncomeTaxPositionsRecognized	0.50
CY2018	bioc	Percent Of Uncertain Income Tax Positions Recognized PercentOfUncertainIncomeTaxPositionsRecognized	0.50
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3699532
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9229174
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2686665
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2958710
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2560419
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2864028
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	90866
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	64628
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9037482
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15116540
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9037482
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15116540
CY2018Q4	bioc	Percentage Of Change In Ownership PercentageOfChangeInOwnership	0.50
CY2018	bioc	Period Of Change In Ownership PeriodOfChangeInOwnership	P3Y
CY2018	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-07-31
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1272000
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1272000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1430366
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	855136
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2285502
CY2017	bioc	Capital Leases Sales Tax And Maintenance Obligations Expense CapitalLeasesSalesTaxAndMaintenanceObligationsExpense	79000
CY2018	bioc	Capital Leases Sales Tax And Maintenance Obligations Expense CapitalLeasesSalesTaxAndMaintenanceObligationsExpense	101000
CY2017Q1	us-gaap	Cash Cash	14042388
CY2017Q2	us-gaap	Cash Cash	10000155
CY2017Q3	us-gaap	Cash Cash	5879025
CY2017Q1	us-gaap	Assets Assets	17933413
CY2017Q2	us-gaap	Assets Assets	14653193
CY2017Q3	us-gaap	Assets Assets	11120215
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2062544
CY2017Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1561520
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1255939
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1421527
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	10418069
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	7342257
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	4026079
CY2017Q1	us-gaap	Revenues Revenues	1683065
CY2017Q2	us-gaap	Revenues Revenues	1278961
CY2017Q3	us-gaap	Revenues Revenues	1111411
CY2017Q4	us-gaap	Revenues Revenues	995226
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	2129454
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	2368705
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	2487054
CY2017Q4	us-gaap	Cost Of Revenue CostOfRevenue	2359909
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	757258
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	841991
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	856698
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	908800
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1906635
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1798026
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1834771
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1650097
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1278311
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1746867
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1675852
CY2017Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1642941
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4388593
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5476628
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5742964
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5566521
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-4432707
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5693151
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5821306
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-5666573
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.27
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.32
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.85
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.36
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.27
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.32
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.85
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.36
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	707389
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	901007
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	995254
CY2018Q3	us-gaap	Cash Cash	8956200
CY2018Q1	us-gaap	Assets Assets	14747827
CY2018Q2	us-gaap	Assets Assets	8291310
CY2018Q3	us-gaap	Assets Assets	14551892
CY2018Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1357193
CY2018Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1258261
CY2018Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1174397
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6038862
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1058055
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	707389
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	901007
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	995254
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1058055
CY2018Q1	us-gaap	Cash Cash	9272420
CY2018Q2	us-gaap	Cash Cash	2569111
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1098137
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	8507714
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	2527568
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	8938408
CY2018Q1	us-gaap	Revenues Revenues	806943
CY2018Q2	us-gaap	Revenues Revenues	822238
CY2018Q3	us-gaap	Revenues Revenues	761591
CY2018Q4	us-gaap	Revenues Revenues	859526
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	2434886
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	2699671
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	2481916
CY2018Q4	us-gaap	Cost Of Revenue CostOfRevenue	2435262
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1070584
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1019285
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1089746
CY2018Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1288957
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1938664
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1708970
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1793720
CY2018Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1632670
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1636542
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1433174
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1404192
CY2018Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1440798
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6273733
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6007983
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5938161
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6356404
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-6153101
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6047784
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-6014312
CY2018Q3	bioc	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	636370
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6356404
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6153101
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6684154
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6014312
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.33
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.70
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.42
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.33
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.70
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.42
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1911282
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2280115
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2767440
CY2018Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4209221
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1911282
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2280115
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2759614
CY2018Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4209221

Files In Submission

Name	View Source	Status
0001564590-19-009914-index-headers.html	Edgar Link	pending
0001564590-19-009914-index.html	Edgar Link	pending
0001564590-19-009914.txt	Edgar Link	pending
0001564590-19-009914-xbrl.zip	Edgar Link	pending
bioc-10k_20181231.htm	Edgar Link	pending
bioc-20181231.xml	Edgar Link	completed
bioc-20181231.xsd	Edgar Link	pending
bioc-20181231_cal.xml	Edgar Link	unprocessable
bioc-20181231_def.xml	Edgar Link	unprocessable
bioc-20181231_lab.xml	Edgar Link	unprocessable
bioc-20181231_pre.xml	Edgar Link	unprocessable
bioc-ex231_250.htm	Edgar Link	pending
bioc-ex311_8.htm	Edgar Link	pending
bioc-ex312_7.htm	Edgar Link	pending
bioc-ex321_6.htm	Edgar Link	pending
bioc-ex322_9.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIOCQ
Biocept Inc Stock $biocq

2019 Q1 Form 10-K Financial Statement

#000156459019009914 Filed on March 29, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOCQ Biocept Inc Stock $biocq

2019 Q1 Form 10-K Financial Statement

#000156459019009914 Filed on March 29, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIOCQ
Biocept Inc Stock $biocq